| # | Drug | Count |
|---|---|---|
| 0 | ATEZOLIZUMAB | 35 |
| 1 | CARBOPLATIN | 32 |
| 2 | ETOPOSIDE | 28 |
| 3 | PEMBROLIZUMAB | 19 |
| 4 | NIVOLUMAB | 13 |
| 5 | DURVALUMAB | 11 |
| 6 | BEVACIZUMAB | 6 |
| 7 | METHYLPREDNISOLONE | 6 |
| 8 | RITUXIMAB | 6 |
| 9 | CISPLATIN | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-MALY | 1 | 0.0050 |
| 1 | HYALURONATE SODIUM | 2 | 0.0013 |
| 2 | SENNOSIDES A AND B | 2 | 0.0012 |
| 3 | BACILLUS CALMETTE-GUERIN | 2 | 0.0011 |
| 4 | UREA | 2 | 0.0009 |
| 5 | ATEZOLIZUMAB | 35 | 0.0009 |
| 6 | DURVALUMAB | 11 | 0.0005 |
| 7 | AVELUMAB | 2 | 0.0005 |
| 8 | ETOPOSIDE | 28 | 0.0004 |
| 9 | PALONOSETRON HYDROCHLORIDE | 2 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Live Attenuated Bacillus Calmette-Guerin Immunotherapy [EPC] | 2 | 0.0011 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 67 | 0.0007 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 13 | 0.0006 |
| 3 | Topoisomerase Inhibitor [EPC] | 28 | 0.0004 |
| 4 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 2 | 0.0002 |
| 5 | Quinolone Antimicrobial [EPC] | 2 | 0.0002 |
| 6 | Platinum-based Drug [EPC] | 37 | 0.0001 |
| 7 | Human Immunoglobulin G [EPC] | 2 | 0.0001 |
| 8 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 2 | 0.0001 |
| 9 | Vasopressin V2 Receptor Antagonist [EPC] | 1 | 0.0001 |